More than 75 percent of aesthetic patients rated the value of a new procedure to clear lesions as higher than other popular aesthetic procedure, according to a survey by Pulse Biosciences.

A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting.

A diverse sample of 405 aesthetic patients in the U.S. who are likely to pay cash to improve their skin condition participated in the online survey. Participants with the target lesions were provided a procedure description modeling the potential CellFX profile and its unique cell- specific NPS mechanism, as well as before and after photos from controlled clinical studies of target lesions. Results indicated that on average 76 percent of aesthetic patients rated the value of a new procedure to clear lesions as higher than other popular aesthetic procedures, such as botulinum toxin or fillers, that they have paid for in the past, and would prioritize clearing lesions over these other common available procedures.

“We see many aesthetic patients with visible skin lesions that have a substantial impact on their psychosocial health and quality of life. More than a nuisance, these skin lesions often become a burden affecting patients in terms of their physical appearance, self-confidence and other important aspects of life,” says Thomas Rohrer, MD, a leading dermatologic surgeon at the SkinCare Physicians Group of Chestnut Hill, Massachusetts, in a news release. “This study of patient perceptions reminds us that patients have their own preferences and priorities regarding treatments that are important. In the case of patients with unwanted benign lesions, a majority report they are highly motivated to seek a solution that provides both clinical efficacy and improved aesthetic results.”

“This consumer research was conducted to better understand unmet needs, particularly the benefit and economic value of clearing common lesions for these aesthetic patients,” says Darrin Uecker, CEO and President of Pulse Biosciences. “We were pleased that the findings validated a genuine patient desire for a long-lasting solution to clear lesions that produces a visible, clear difference that contributes to how they look and feel.”

The CellFX System harnesses the advantages of the Company’s proprietary Nano- Pulse Stimulation (NPSTM) technology, which delivers nano-second pulses of electrical energy.

Pulse Biosciences also announced the launch of its new CellFX.com website.